Artelo Biosciences, Inc. (ARTL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ARTL Stock Price Chart Interactive Chart >
ARTL Price/Volume Stats
|Current price||$0.32||52-week high||$1.32|
|Prev. close||$0.30||52-week low||$0.28|
|Day high||$0.32||Avg. volume||945,755|
|50-day MA||$0.34||Dividend yield||N/A|
|200-day MA||$0.52||Market Cap||13.32M|
Artelo Biosciences, Inc. (ARTL) Company Bio
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
Most Popular Stories View All
ARTL Latest News Stream
|Loading, please wait...|
ARTL Latest Social Stream
View Full ARTL Social Stream
Latest ARTL News From Around the Web
Below are the latest news stories about Artelo Biosciences Inc that investors may wish to consider to help them evaluate ARTL as an investment opportunity.
Happy Friday, trader!
Artelo Biosciences (ARTL): FQ1 GAAP EPS of -$0.08 misses by $0.02.As of November 30, 2021, the company had ~$26.4M in cash and marketable securities, compared to $10.07M as of August
Artelo Biosciences Reports First Quarter Fiscal Year 2022 Financial Results and Provides Business Update
Complete Enrollment of Phase 1 CAReS Trial Anticipated by End of First Quarter of Calendar Year 2022 $26.4 Million in Cash and Marketable Securities as of November 30, 2021 SOLANA BEACH, Calif., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today reported financial and operating results for the first quarter of its fiscal year
Grab a cup of coffee and get ready for another busy day of trading as we start with the biggest pre-market stock movers for Tuesday!
Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom
SOLANA BEACH, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) announced that the United Kingdom’s Home Office has classified the Company’s lead clinical cannabinoid, ART27.13, as “non-controlled” and, therefore, is no longer considered a Schedule 1 controlled substance, which would impose limitations on its production, possession, and supply. The Home Office is the lead government department tasked with major economic, security and safety policies, including dru
ARTL Price Returns